You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Lymph Node Ratio-based Staging System Outperforms the Seventh AJCC System for Gastric Cancer: Validation Analysis With National Taiwan University Hospital Cancer Registry

Lee, Yueh-Chang MD, MPH; Yang, Po-Jen MD; Zhong, Yuxin MD; Clancy, Thomas E. MD; Lin, Ming-Tsan MD, PhD; Wang, Jiping MD, MSc, PhD

American Journal of Clinical Oncology:
doi: 10.1097/COC.0000000000000110
Original Articles: Gastrointestinal
Abstract

Background: On the basis of SEER data, in which most gastric cancer patients had limited lymph node dissection, node ratio–based staging system (TNrM) has been shown to have better accuracy than the AJCC TNM system. This study is to validate the result with patients from Taiwan, where D2 lymphadenectomy is routinely performed.

Patient and Method: A total of 1405 consecutive gastric cancer patients treated at National Taiwan University Hospital between 1998 and 2010 were included. To evaluate the performance of the AJCC system, each TNM stage was stratified by TNrM stages. The homogeneity of patients’ survival across TNrM strata was evaluated using the log-rank test. The performance of the TNrM system was evaluated with the same approach.

Results: Five of the 7 evaluable AJCC stages (IA, IIA, IIIA, IIIB, and IIIC) contained TNrM subgroups with statistically heterogenous survival (P=0.003, 0.04, 0.002, 0.04, and <0.001, respectively). Thirty-six percent of patients (506/1405) were misclassified by the AJCC TNM system. However, of the assessable 6 TNrM stages, none of the AJCC subgroups showed significantly heterogenous survivals (P>0.05). About 19% of patients (264/1405) were misclassified by using the TNrM system.

Conclusions: Lymph node ratio significantly decreases the stage migration caused by inadequate examined lymph nodes. The advantage of TNrM was validated with a patient cohort from the Eastern medical center.

Author Information

*Harvard School of Public Health

§Division of Surgical Oncology, Brigham and Women’s Hospital

Department of Surgery, Harvard Medical School, Boston, MA

Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan

Cancer Hospital & Cancer Institute, Chinese Academy of Medical Science, Beijing

The authors declare no conflicts of interest.

Reprints: Jiping Wang, MD, MSc, Division of Surgical Oncology, Brigham and Women’s Hospital, 75 Francis Street, Carrie Hall, 3rd Fl, Boston, MA 02115. E-mail: jwang39@partners.org.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.